Restricted accessResearch articleFirst published online 2018-11
Dexmedetomidine Mitigates Microglia-Mediated Neuroinflammation through Upregulation of Programmed Cell Death Protein 1 in a Rat Spinal Cord Injury Model
Excessive neuroinflammation aggravates neurological damage after spinal cord injury (SCI). Controlling neuroinflammation might favor neuroregeneration and tissue repair. Dexmedetomidine is reported to inhibit post-SCI neuroinflammation in previous research. In the current study, to determine the mechanisms by which dexmedetomidine inhibits neuroinflammation, we tested the effect of dexmedetomidine hydrochloride on microglia in vitro and in a rat SCI model. We found that dexmedetomidine hydrochloride up-regulated programmed cell death protein 1 (PD-1), an immunoregulatory molecule, in activated microglia but not in resting microglia. In the presence of programmed death-ligand 1 (PD-L1), this enhanced PD-1 expression downregulated pro-inflammatory cytokine expression and upregulated anti-inflammatory cytokine expression in activated microglia. PD-L1/PD-1 engagement also induced microglia polarization toward the immunoregulatory M2 type. Moreover, dexmedetomidine hydrochloride promoted 5' adenosine monophosphate-activated protein kinase (AMPK) signaling in activated microglia. AMPK signaling was responsible for the above-mentioned changes of cytokine expression and M2 microglia polarization. Consistently, intraperitoneal injection of dexmedetomidine hydrochloride had a similar effect on microglia in the rat SCI model. Taken together, our study disclosed a novel mechanism underlying the anti-neuroinflammatory effect of dexmedetomidine: dexmedetomidine promotes AMPK signaling in activated microglia via upregulation of microglial PD-1 expression, and subsequently drives microglia polarization toward M2 type.
Get full access to this article
View all access options for this article.
References
1.
SilvaN.A., SousaN., ReisR.L., and SalgadoA.J. (2014). From basics to clinical: a comprehensive review on spinal cord injury. Prog. Neurobiol., 114, 25–57.
2.
TrivediA., OlivasA.D., and Noble-HaeussleinL.J. (2006). Inflammation and spinal cord injury: infiltrating leukocytes as determinants of injury and repair processes. Clin. Neurosci. Res., 6, 283–292.
3.
CarsonM.J., ThrashJ.C., and WalterB. (2006). The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survival. Clin. Neurosci. Res., 6, 237–245.
BeattieM.S. (2004). Inflammation and apoptosis: linked therapeutic targets in spinal cord injury. Trends Mol. Med., 10, 580–583.
6.
LoaneD.J. and ByrnesK.R. (2010). Role of microglia in neurotrauma. Neurotherapeutics, 7, 366–377.
7.
CherryJ.D., OlschowkaJ.A., and O'BanionM.K. (2014). Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation, 11, 98.
8.
ZhouX., HeX., and RenY. (2014). Function of microglia and macrophages in secondary damage after spinal cord injury. Neural Regen. Res., 9, 1787–1795.
9.
NakajimaH., UchidaK., GuerreroA.R., WatanabeS., SugitaD., TakeuraN., YoshidaA., LongG., WrightK.T., JohnsonW.E., and BabaH. (2012). Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury. J. Neurotrauma, 29, 1614–1625.
10.
KeirM.E., ButteM.J., FreemanG.J., and SharpeA.H. (2008). PD-1 and its ligands in tolerance and immunity. Ann. Rev. Immunol., 26, 677–704.
ZhuY.J., PengK., MengX.W., and JiF.H. (2016). Attenuation of neuroinflammation by dexmedetomidine is associated with activation of a cholinergic anti-inflammatory pathway in a rat tibial fracture model. Brain Res. 1644, 1–8.
13.
UekiM., KawasakiT., HabeK., HamadaK., KawasakiC., and SataT. (2014). The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. Anaesthesia, 69, 693–700.
14.
LiB., LiY., TianS., WangH., WuH., ZhangA., and GaoC. (2015). Anti-inflammatory effects of perioperative dexmedetomidine administered as an adjunct to general anesthesia: a meta-analysis. Sci. Rep., 5, 12342.
15.
InadaT., SumiC., HirotaK., ShinguK., OkamotoA., MatsuoY., and KamibayashiT. (2017). Mitigation of inflammation using the intravenous anesthetic dexmedetomidine in the mouse air pouch model. Immunopharmacol. Immunotoxicol., 39, 225–232.
16.
XiangH., HuB., LiZ.,and LiJ. (2014). Dexmedetomidine controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Inflammation, 37, 1763–1770.
17.
ZhangJ., WangZ., WangY., ZhouG., and LiH. (2015). The effect of dexmedetomidine on inflammatory response of septic rats. BMC Anesthesiol. 15, 68.
18.
CelikF., GocmezC., KamasakK., TufekA., GuzelA., TokgozO., FiratU., and EvliyaogluO. (2013). The comparison of neuroprotective effects of intrathecal dexmedetomidine and metilprednisolone in spinal cord injury. Int. J. Surg., 11, 414–418.
19.
RongH., ZhaoZ., FengJ., LeiY., WuH., SunR., ZhangZ., HouB., ZhangW., SunY., GuX., MaZ., and LiuY. (2017). The effects of dexmedetomidine pretreatment on the pro- and anti-inflammation systems after spinal cord injury in rats. Brain Behav. Immun., 64, 195–207.
20.
CanM., GulS., BektasS., HanciV., and AcikgozS. (2009). Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury. Acta Anaesthesiol. Scand., 53, 1068–1072.
BellM.T., AgostonV.A., FreemanK.A., PuskasF., HersonP.S., MaresJ., FullertonD.A., and ReeceT.B. (2014). Interruption of spinal cord microglial signaling by alpha-2 agonist dexmedetomidine in a murine model of delayed paraplegia. J. Vasc. Surg., 59, 1090–1097.
23.
PengM., WangY.L., WangC.Y., and ChenC. (2013). Dexmedetomidine attenuates lipopolysaccharide-induced proinflammatory response in primary microglia. J. Surg. Res., 179, e219–e225.
24.
ZhangX., WangJ., QianW., ZhaoJ., SunL., QianY., and XiaoH. (2015). Dexmedetomidine inhibits inducible nitric oxide synthase in lipopolysaccharide-stimulated microglia by suppression of extracellular signal-regulated kinase. Neurol. Res., 37, 238–245.
25.
D'MelloC., LeT., and SwainM.G. (2009). Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci., 29, 2089–2102.
26.
PatsoukisN., BardhanK., ChatterjeeP., SariD., LiuB., BellL.N., KarolyE.D., FreemanG.J., PetkovaV., SethP., LiL., and BoussiotisV.A. (2015). PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 6, 6692.
27.
ZhangM., ZhuH., DingY., LiuZ., CaiZ., and ZouM.H. (2017). AMP-activated protein kinase alpha1 promotes atherogenesis by increasing monocyte-to-macrophage differentiation. J. Biol. Chem., 292, 7888–7903.
28.
SinclairM.D. (2003). A review of the physiological effects of alpha2-agonists related to the clinical use of medetomidine in small animal practice. Can. Vet. J., 44, 885–897.
29.
MaD., RajakumaraswamyN., and MazeM. (2004). alpha2-Adrenoceptor agonists: shedding light on neuroprotection?. Br. Med. Bull., 71, 77–92.
30.
JonesS.B., HalendaS.P., and BylundD.B. (1991). Alpha 2-adrenergic receptor stimulation of phospholipase A2 and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms. Mol. Pharmacol., 39, 239–245.
31.
YanagawaY., MatsumotoM., and TogashiH. (2010). Enhanced dendritic cell antigen uptake via alpha2 adrenoceptor-mediated PI3K activation following brief exposure to noradrenaline. J. Immunol., 185, 5762–5768.
32.
UllrichS. and WollheimC.B. (1984). Islet cyclic AMP levels are not lowered during alpha 2-adrenergic inhibition of insulin release. J. Biol. Chem., 259, 4111–4115.
33.
ParisH., GalitzkyJ., and SenardJ.M. (1989). Interactions of full and partial agonists with HT29 cell alpha 2-adrenoceptor: comparative study of [3H]UK-14,304 and [3H]clonidine binding. Mol. Pharmacol., 35, 345–354.
34.
BallyA.P., LuP., TangY., AustinJ.W., ScharerC.D., AhmedR., and BossJ.M. (2015). NF-kappaB regulates PD-1 expression in macrophages. J. Immunol., 194, 4545–4554.
35.
GerloS., KooijmanR., BeckI.M., KolmusK., SpoorenA., and HaegemanG. (2011). Cyclic AMP: a selective modulator of NF-kappaB action. Cell. Mol. Life Sci., 68, 3823–3841.
36.
ZhongH., VollR.E., and GhoshS. (1998). Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell, 1, 661–671.
37.
IshinagaH., JonoH., LimJ.H., KweonS.M., XuH., HaU.H., XuH., KogaT., YanC., FengX.H., ChenL.F., and LiJ.D. (2007). TGF-beta induces p65 acetylation to enhance bacteria-induced NF-kappaB activation. EMBO J. 26, 1150–1162.
38.
MinguetS., HuberM., RosenkranzL., SchamelW.W., RethM., and BrummerT. (2005). Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur. J. Immunol., 35, 31–41.
39.
HertzL., LovattD., GoldmanS.A., and NedergaardM. (2010). Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem. Int., 57, 411–420.
40.
EbersoltC., PerezM., and BockaertJ. (1981). Alpha 1 and alpha 2 Adrenergic receptors in mouse brain astrocytes from primary cultures. J. Neurosci. Res., 6, 643–652.
41.
PiazzaO., StaianoR.I., De RobertisE., ContiG., Di CrescenzoV., LoffredoS., MaroneG., MarinosciG.Z., and CataldiM.M. (2016). Effect of alpha2-adrenergic agonists and antagonists on cytokine release from human lung macrophages cultured in vitro. Transl. Med. UniSa, 15, 67–73.
42.
WeatherbyK.E., ZwillingB.S., and LafuseW.P. (2003). Resistance of macrophages to Mycobacterium avium is induced by alpha2-adrenergic stimulation. Infect. Immunol., 71, 22–29.
43.
MoriK., OzakiE., ZhangB., YangL., YokoyamaA., TakedaI., MaedaN., SakanakaM., and TanakaJ. (2002). Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology, 43, 1026–1034.
44.
GyonevaS. and TraynelisS.F. (2013). Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J. Biol. Chem., 288, 15291–15302.
45.
ChenG., KimY.H., LiH., LuoH., LiuD.L., ZhangZ.J., LayM., ChangW., ZhangY.Q., and JiR.R. (2017). PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat. Neurosci., 20, 917–926.
46.
KimH.R., HaS.J., HongM.H., HeoS.J., KohY.W., ChoiE.C., KimE.K., PyoK.H., JungI., SeoD., ChoiJ., ChoB.C., and YoonS.O. (2016). PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci. Rep., 6, 36956.
47.
YaoA., LiuF., ChenK., TangL., LiuL., ZhangK., YuC., BianG., GuoH., ZhengJ., ChengP., JuG., and WangJ. (2014). Programmed death 1 deficiency induces the polarization of macrophages/microglia to the M1 phenotype after spinal cord injury in mice. Neurotherapeutics, 11, 636–650.
48.
WuJ., SunL., LiH., ShenH., ZhaiW., YuZ., and ChenG. (2017). Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype. J. Neuroinflammation, 14, 36.
49.
ChenW., WangJ., JiaL., LiuJ. and TianY. (2016). Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell Death Dis. 7, e2115.
50.
HardieD.G., RossF.A., and HawleyS.A. (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Moll. Cell Biol., 13, 251–262.
51.
MounierR., TheretM., ArnoldL., CuvellierS., BultotL., GoranssonO., SanzN., FerryA., SakamotoK., ForetzM., ViolletB., and ChazaudB. (2013). AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 18, 251–264.
52.
ChenC.C., LinJ.T., ChengY.F., KuoC.Y., HuangC.F., KaoS.H., LiangY.J., ChengC.Y., and ChenH.M. (2014). Amelioration of LPS-induced inflammation response in microglia by AMPK activation. BioMed Res. Int., 2014, 692061.
53.
OrihuelaR., McPhersonC.A., HarryG.J. (2016). Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol., 173, 649–665.
54.
TngY. andLeW. (2016). Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol., 53, 1181–1194.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
